A Study of JNJ-77242113 for the treatment of participants with moderate to severe plaque psoriasis

Phase 3

• Conditions: Plaque psoriasis; Skin and Connective Tissue Diseases

• Registration Number: ISRCTN69978417
• Lead Sponsor: Janssen-Cilag International N.V.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-08
• Last Update Posted: 6 May 2024
• Study Completion: 2027-06-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

1. Aged 18 years or older;
2. Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks before the first administration of study intervention
3. Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline;
4. Total psoriasis area and severity index (PASI) >=12 at screening and baseline;
5. Total investigator global assessment (IGA) >=3 at screening and baseline;
6. Candidate for phototherapy or systemic treatment for plaque psoriasis.

Exclusion Criteria

1. Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular);
2. Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium);
3. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, haematologic, rheumatologic, psychiatric, or metabolic disturbances;
4. Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients;
5. Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified